Design, synthesis and biological evaluation of novel bischalcone derivatives as potential anticancer agents

Building on our previous work that discovered chalcone as a promising pharmacophore for anticancer activity, we have various other chalcone derivatives and have synthesized a series of novel bischalcone to explore their anticancer activity. Among all tested compounds, compounds 6a, 6b, and 6c showed the highest antiproliferative activity against A-549 cancer cell lines with the average IC50 values of 4.18, 4.52, and 5.05 & micro;M, respectively. Moreover, compound 6c showed high antiproliferative activity against the Caco-2 cell line; thus, it was 2- and 4fold more active than the reference compounds, i.e., methotrexate and capecitabine. Compound 6a also induced cell-cycle arrest in the S phase, whereas compounds 6b and 6c were observed to stop at the G0/G1 phase. Thereafter, we evaluated that compound 6c also had the highest apoptosis/necrosis ratio than other compounds and the standard compound. The anticancer property of the 6c was also supported by molecular docking studies carried out on the EGFR and HER2 receptors. Overall, we expect that these compounds can be further developed for the potential treatment of lung cancer.

Automated summary

Building on previous work on chalcone as a pharmacophore for anticancer activity, the study synthesized novel bischalcones and found compound 6c to exhibit the highest antiproliferative activity, induce cell cycle arrest, and have a high apoptosis/necrosis ratio. Molecular docking studies supported its anticancer properties, suggesting its potential for lung cancer treatment.